Strategies and Solutions for Publication Planning and Execution Excellence

Strategies and Solutions for Publication Planning and Execution Excellence

The reputation of the global pharmaceutical industry is currently suffering, and there is public mistrust of drug companies' publication practices. The industry can only eradicate this problem through increased transparency, honesty and openness in its publications. Clearly, the provision of unbiased information to medical decision makers is essential, not only for the sake of the industry's image, but, more importantly, for the good of public health.

In an environment of rapidly changing rules and regulations, pharmaceutical companies must develop their own robust publication policies that reflect the latest guidelines. Crucially, they must also develop compliance programmes to ensure that all those working on publications not only understand company policy, but actively implement it.

This KeywordPharma Conference Insights review from NetworkPharma Ltd provides an in-depth review of the 5th Annual Meeting of The International Publication Planning Association held in San Francisco, CA, 25-26 June 2007. It details the major challenges facing publications professionals, including the need for disclosure, transparency and compliance. It offers guidance on how to develop and implement company policy, looks at the involvement of marketing in the publication process, the growth of open-access publishing and how agencies and drug companies can develop effective partnerships.

Contents

The world of medical publishing is complicated and fast-moving. It involves complex relationships between journal editors, academic investigators and publication professionals working in or for pharmaceutical companies. The 5th Annual Meeting of The International Publication Planning Association (TIPPA) highlighted the need for companies to keep abreast of the latest rules and regulations and to develop guidelines and policies to improve the publication planning process. Such improvements may, in turn, help repair the image of the sector, and restore public trust in industrysponsored publications which has been damaged recently.

A wide range of issues was addressed. Transparency, disclosure and compliance emerged as keywords. The need to develop and maintain robust company policies that refl ect changing publications requirements was also noted. In addition, the meeting looked at authorship guidelines, the latest developments in results disclosure, and the impact of costcutting and globalisation on publication planning.

The publication planning process requires cooperation from a diverse group of people and input from a number of different sources. Coordinating such teams and drawing together such information to create transparent, unbiased and educational documents for publication is a major challenge. Likewise, creating, maintaining and enforcing effective company policies can be challenging.

The 5th TIPPA meeting provided a valuable information exchange for stakeholders across the industry, offering practical guidance for all those seeking publication planning and execution excellence.

Contents

• Strategies and Solutions for Publication Planning and Execution Excellence - Programme
• Introduction
• About the author
• Legal issues
• An editor's perspective
• The role of marketing in developing publications
• Payments for authors
• Developing a company publication policy
• Leading publication teams
• Problems with authorship
• Effects of cost-cutting and global sourcing
• The latest on open-access publishing
• Developments in results disclosure
• Conclusions
• References

About The Author

Elizabeth (Liz) Wager is the author of books on 'Getting Research Published: An A to Z of Publication Strategy' and 'How to Survive Peer Review'. She is a co-author of 'Good Publication Practice for Pharmaceutical Companies' and the European Medical Writers Association guidelines on the role of medical writers. After obtaining a First Class zoology degree from Oxford in 1983 she worked for Blackwell Scientific Publications, Janssen-Cilag then Glaxo-Wellcome. In 2001, she set up her own company, Sideview, which provides training, writing, editing and publication consultancy services. She is a member of: the BMJ's Ethics Committee, the World Association of Medical Editors Ethics Committee, the Council of the Committee on Publication Ethics, the editorial board of European Science Editing (the journal of the European Association of Science Editors) and the World Health Organization Scientific Advisory Group on trial registration.

Programme

Co-Chairs:

Dan Donovan, Founder and President, Envision Pharma

Jodie M Sherman Gillon, Associate Director, Publications Management Team, Pfizer Inc.

Day one

• Legal and Regulatory Update on Publication Planning and Dissemination
• James H Smith, Associate Chief Counsel, Office of General Counsel - US Food and Drug Administration
• Ioana Petrou, Chief, Major Crimes, Criminal Health Care
• Fraud Coordinator, US Attorney's Office, NDCA
• Alan Minsk, Partner and Leader, Food and Drug Practice Group, Arnall Golden Gregory LLP

• An Editor's Perspective: The Outlook for the Convergence of Journal Requirements
• Trish Groves, Deputy Editor and Sr. Research Editor, British Medical Journal
• Academia and Industry: Strategies for Positive Collaboration
• Thomas P Stossel, American Cancer Society Clinical Research Professor, Harvard Medical School; Co-Director, Hematology Division, Brigham & Women's Hospital

• Point-Counterpoint: Is There a Role for Marketing? What About Payment for Publication?
• Jodie M Sherman Gillon, Associate Director, Publications Management Team, Pfizer Inc.
• Jessica Colon, Associate Director Clinical Communications, Global Clinical Development & Medical Affairs, Novartis Pharmaceuticals Corporation

Day two

• Industry Panel: Developing and Maintaining a Company Wide Publication Policy
• Elizabeth Crane, Assistant Director, Publications, TAP Pharmaceutical Products Inc.
• Jessica Colon, Associate Director Clinical Communications, Global Clinical Development & Medical Affairs, Novartis Pharmaceuticals Corporation
• Michael Petrarca, Director of Medical Writing, Amgen Inc.
• Fostering Effective Publication Planning Team Dynamics
• Lynda C McDermott, President, EquiPro International Ltd
• Clearly Identifying Authors in the World of Guest and Ghost Authorship
• Neil W Matheson, CEO, Axis Healthcare Communications, LLC
• Discussion Tables
• Moderator: Kevin G. Doty, Director Client Development, Complete Healthcare Communications, Inc.
• Survival in the Wake of Cost Cutting and Global Sourcing Initiatives
• Dan Donovan, Founder and President, Envision Pharma
• Joseph Haldey, Senior Associate Director-Medical Publications Department, Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
• Varying Perspectives: The Latest on Open Access Publishing vs. the Traditional Journal Model
• Barbara Cohen, Senior Editor, PLoS Medicine
• Peter Banks, Founder, Banks Publishing

An Industry Roundtable on Results Disclosure

• Moderator: Art Gertel, Vice President of Clinical Services, Regulatory, and Medical Writing, Beardsworth
• Panellists: Ida Sim, Associate Professor of Medicine, University of California San Francisco, Past Project Coordinator, International Clinical Trials Registry Platform, World Health Organization
• Emma Veitch, Publications Manager, PLoS Clinical Trials
• Pamela A Rose, Director, Clinical Trial Information Registries, TAP Pharmaceutical Products Inc.

• Career Management: The Outlook for Publication Planning Professionals (and other information your manager preferred you didn't know)
• Michelle Poloni, Project Manager, Pharmaceutical and Biotechnology, Management Recruiters of Vancouver, LLC

Related products